CoChat

Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers

Krishnan, Suma M., Stark, Jeffrey G. · 2008 · Current Medical Research and Opinion

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To evaluate the pharmacokinetics of lisdexamfetamine dimesylate (LDX; Vyvanse) in fasting healthy adult volunteers. BACKGROUND: LDX is the first pro-drug stimulant and is indicated for the treatment of attention-deficit/hyperactivity disorder. LDX was developed with the goal of providing an extended effect that is consistent throughout the day, with a reduced potential for abuse, overdose toxicity, and drug tampering. METHODS: This was an open-label, multipledose phase 1 study. LDX 70 mg/d was administered in the morning to 12 subjects for 7 days. Twenty blood samples were drawn during the study. Descriptive statistics were used for pharmacokinetic parameters. RESULTS: Based on C(min), steady-state d-amphetamine concentration (20.6 ng/mL) was reached by day 5, whereas LDX was undetectable, and 95% of the d-amphetamine was eliminated within 48 hours following the final dose on day 7. At steady state, d-amphetamine achieved a mean +/- standard deviation C(max) of 90.1 +/- 29.6 ng/mL, with a median T(max) of 3.0 hours. The AUC(0-inf) for d-amphetamine was 1453 +/- 645.7 ng.h/mL. Complete elimination of the pro-drug occurred approximately 6 hours following the final dose on day 7. Adverse events were mild to moderate and similar to other oral amphetamines. CONCLUSIONS: This study describes the steady-state pharmacokinetics of LDX, a new pro-drug stimulant. Possible study limitations include an open-label design and a small sample size.

Overview

Integrity signals

Registry

Crossref · 10.1185/030079908x242737

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 14 references

Cited by

See all 55

Metadata

Authors
Krishnan, S. M., & Stark, J. G.
Affiliations
  • New River Pharmaceuticals Radford, VAUSA (formerly)
  • Center for Diagnosis and Research on Alzheimer's Disease (CA)
Corresponding author
Krishnan, Suma M.
Venue
Current Medical Research and Opinion
Published
2007-11-14
Volume
24
Issue
1
Pages
33-40
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
OpenAlex
W2073171215
Cited by
55
References
14
Citations by year
2025: 3 · 2024: 3 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 2 · 2017: 2 · 2016: 7 · 2015: 1 · 2014: 2 · 2013: 3 · 2012: 4
FWCI
3.84
Type
journal article
Language
en
Open access
closed
Locations
  • Current Medical Research and Opinion (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
lisdexamfetamine dimesylate, Vyvanse, pharmacokinetics, multiple daily dosing, d-amphetamine, attention deficit hyperactivity disorder, steady-state concentration, drug elimination, adverse events
MeSH terms
Lisdexamfetamine Dimesylate, Adult, Central Nervous System Stimulants, Dextroamphetamine, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Health, Humans, Human Experimentation, Male, Middle Aged, Prodrugs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. https://app.cochat.ai/papers/10.1185/030079908x242737
The paper
Krishnan, S. M., & Stark, J. G. (2008). Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. Current Medical Research and Opinion. https://doi.org/10.1185/030079908x242737

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.